No Data
Selling Amylyx Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $10
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $12
Express News | HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $12 Price Target
Express News | Amylyx Pharmaceuticals Shares up 1.7% on Late-Stage Trial Update for Low-Blood Sugar Drug
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
No Data
